Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002 Aug;110(3):285-8.
doi: 10.1172/JCI16421.

Isoprenoids as mediators of the biological effects of statins

James K Liao  1
Affiliations
Review

Isoprenoids as mediators of the biological effects of statins

James K Liao. J Clin Invest. 2002 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Biological actions of isoprenoids and cholesterol. This diagram of the cholesterol biosynthesis pathway shows the effects of inhibition of HMG-CoA reductase by statins. Decrease in isoprenylation of signaling molecules such as Ras, Rho, and Rac leads to modulation of various signaling pathways. BMP-2, bone morphogenetic protein-2; eNOS, endothelial nitric oxide synthase; t-PA, tissue-type plasminogen activator; ET-1, endothelin-1; PAI-1, plasminogen activator inhibitor-1.
Figure 2
Figure 2
Actin cytoskeletal effects of statins. Phalloidin staining of human endothelial cells shows the effects of the statin simvastatin (10 μM) on actin stress fibers and focal adhesion complexes (green) with and without L-mevalonate (L-Mev, 200 μM).
Figure 3
Figure 3
Antioxidant effects of statins. Intracellular oxidation (red) as determined by 2′,7′-dichlorofluoroscein staining of rat cardiomyocytes treated with angiotensin II (Ang II, 10 nM), with and without simvastatin (statin, 10 μM), L-mevalonate (L-Mev, 200 μM), GGPP (100 μM), or FPP (100 μM).
See this image and copyright information in PMC

References

    1. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292:1160–1164. - PubMed
    1. Illingworth DR, Tobert JA. HMG-CoA reductase inhibitors. Adv Protein Chem. 2001;56:77–114. - PubMed
    1. McTaggart F, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87:28B–32B. - PubMed
    1. Corsini A, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413–428. - PubMed
    1. Klag MJ, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med. 1993;328:313–318. - PubMed

MeSH terms

Substances